These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 24534923)
21. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice. Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007 [TBL] [Abstract][Full Text] [Related]
22. Role of beta-(1→3)(1→6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures. Boulifa A; Raftery MJ; Franzén AS; Radecke C; Stintzing S; Blohmer JU; Pecher G BMC Cancer; 2024 Mar; 24(1):339. PubMed ID: 38486205 [TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444 [TBL] [Abstract][Full Text] [Related]
24. Growth-inhibitory effects of a beta-glucan from the mycelium of Poria cocos on human breast carcinoma MCF-7 cells: cell-cycle arrest and apoptosis induction. Zhang M; Chiu LC; Cheung PC; Ooi VE Oncol Rep; 2006 Mar; 15(3):637-43. PubMed ID: 16465424 [TBL] [Abstract][Full Text] [Related]
25. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Jiang M; Huang O; Zhang X; Xie Z; Shen A; Liu H; Geng M; Shen K Molecules; 2013 Jan; 18(1):701-20. PubMed ID: 23299550 [TBL] [Abstract][Full Text] [Related]
26. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression. Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501 [TBL] [Abstract][Full Text] [Related]
27. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex. Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412 [TBL] [Abstract][Full Text] [Related]
28. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106 [TBL] [Abstract][Full Text] [Related]
29. Antiproliferative and pro-apoptotic effects of three fungal exocellular β-glucans in MCF-7 breast cancer cells is mediated by oxidative stress, AMP-activated protein kinase (AMPK) and the Forkhead transcription factor, FOXO3a. Queiroz EA; Fortes ZB; da Cunha MA; Barbosa AM; Khaper N; Dekker RF Int J Biochem Cell Biol; 2015 Oct; 67():14-24. PubMed ID: 26255117 [TBL] [Abstract][Full Text] [Related]
30. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells. Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084 [TBL] [Abstract][Full Text] [Related]
31. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression. Zhang B; Zhang X; Tang B; Zheng P; Zhang Y Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650 [TBL] [Abstract][Full Text] [Related]
32. Anacardic Acid, Salicylic Acid, and Oleic Acid Differentially Alter Cellular Bioenergetic Function in Breast Cancer Cells. Radde BN; Alizadeh-Rad N; Price SM; Schultz DJ; Klinge CM J Cell Biochem; 2016 Nov; 117(11):2521-32. PubMed ID: 26990649 [TBL] [Abstract][Full Text] [Related]
33. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer. Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697 [TBL] [Abstract][Full Text] [Related]
34. The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression. Tu Z; Li H; Ma Y; Tang B; Tian J; Akers W; Achilefu S; Gu Y Mol Cell Biochem; 2012 Jul; 366(1-2):111-22. PubMed ID: 22476901 [TBL] [Abstract][Full Text] [Related]
35. Anti-Cancer Potential of Linear β-(1→6)-D-Glucan from Rutckeviski R; Corso CR; Fonseca AS; Rodrigues ML; Román-Ochoa Y; Cipriani TR; Cavalli LR; Cadena SMSC; Smiderle FR Molecules; 2024 Oct; 29(19):. PubMed ID: 39407709 [TBL] [Abstract][Full Text] [Related]
36. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer. Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091 [TBL] [Abstract][Full Text] [Related]
37. FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer. Wang J; Xu Y; Li L; Wang L; Yao R; Sun Q; Du G Cancer Med; 2017 Jan; 6(1):275-287. PubMed ID: 28028927 [TBL] [Abstract][Full Text] [Related]
38. Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. de Cremoux P; Tran-Perennou C; Brockdorff BL; Boudou E; Brünner N; Magdelénat H; Lykkesfeldt AE Endocr Relat Cancer; 2003 Sep; 10(3):409-18. PubMed ID: 14503918 [TBL] [Abstract][Full Text] [Related]
39. A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine-resistant breast cancer cells. Huang O; Xie Z; Zhang W; Lou Y; Mao Y; Liu H; Jiang M; Shen K Oncol Rep; 2014 Aug; 32(2):627-34. PubMed ID: 24919713 [TBL] [Abstract][Full Text] [Related]
40. Ethoxy mansonone G as an anticancer agent in estrogen receptor-positive and endocrine-resistant breast cancer. Chonsut P; Mahalapbutr P; Pradubyat N; Chavasiri W; Wonganan P; Ketchart W J Pharm Pharmacol; 2019 Dec; 71(12):1839-1853. PubMed ID: 31588558 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]